DBV Technologies S.A. Asset Resilience Ratio
DBV Technologies S.A. asset resilience ratio. DBV Technologies S.A. (DBV) has an Asset Resilience Ratio of 28.68% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DBV Technologies S.A. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DBV Technologies S.A. (2007–2025)
Asset resilience ratio of DBV Technologies S.A. from 2007 to 2025. This chart shows how DBV Technologies S.A.'s Asset Resilience Ratio has changed over time. See DBV Technologies S.A. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down DBV Technologies S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is DBV Technologies S.A.'s balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €67.05 Million | 28.68% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €67.05 Million | 28.68% |
Asset Resilience Insights
- Very High Liquidity: DBV Technologies S.A. maintains exceptional liquid asset reserves at 28.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
DBV Technologies S.A. Industry Peers by Asset Resilience Ratio
Compare DBV Technologies S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
DBV Technologies S.A. Asset Resilience Ratio by Year (2007–2025)
DBV Technologies S.A. asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for DBV Technologies S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.68% | €67.05 Million ≈ $78.39 Million |
€233.75 Million ≈ $273.27 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€65.66 Million ≈ $76.76 Million |
-- |
| 2023-12-31 | 64.18% | €117.44 Million ≈ $137.30 Million |
€182.99 Million ≈ $213.93 Million |
-8.47pp |
| 2022-12-31 | 72.65% | €179.09 Million ≈ $209.38 Million |
€246.50 Million ≈ $288.18 Million |
+41.39pp |
| 2021-12-31 | 31.27% | €45.87 Million ≈ $53.63 Million |
€146.72 Million ≈ $171.53 Million |
-14.86pp |
| 2020-12-31 | 46.13% | €154.01 Million ≈ $180.06 Million |
€333.87 Million ≈ $390.33 Million |
+2.02pp |
| 2019-12-31 | 44.11% | €135.37 Million ≈ $158.27 Million |
€306.90 Million ≈ $358.80 Million |
+0.46pp |
| 2018-12-31 | 43.65% | €102.47 Million ≈ $119.79 Million |
€234.76 Million ≈ $274.45 Million |
-50.59pp |
| 2017-12-31 | 94.23% | €235.86 Million ≈ $275.74 Million |
€250.28 Million ≈ $292.61 Million |
+57.60pp |
| 2016-12-31 | 36.64% | €116.20 Million ≈ $135.85 Million |
€317.16 Million ≈ $370.79 Million |
+36.23pp |
| 2013-12-31 | 0.41% | €345.41K ≈ $403.82K |
€84.80 Million ≈ $99.14 Million |
-0.31pp |
| 2009-12-31 | 0.72% | €49.00K ≈ $57.29K |
€6.79 Million ≈ $7.94 Million |
-0.51pp |
| 2008-12-31 | 1.23% | €49.00K ≈ $57.29K |
€3.98 Million ≈ $4.66 Million |
+0.61pp |
| 2007-12-31 | 0.63% | €49.00K ≈ $57.29K |
€7.84 Million ≈ $9.16 Million |
-- |
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more